Biopharmaceuticals Manufacturing Consumables Testing Market - Industry Analysis, Market - Forecast(2025 - 2031)

Biopharmaceuticals Manufacturing Consumables Testing Market Overview

The Biopharmaceuticals Manufacturing Consumables Testing market size is forecast to reach USD 1,107.2 million by 2030, after growing at a CAGR of 9.3% during the forecast period 2025-2030. The consistent growth in manufacturing capabilities of Biopharma is driving the demand for consumables and testing services crucial for ensuring product quality and regulatory compliance. As new production lines are added and existing ones are expanded, the Biopharmaceuticals Manufacturing Consumables Testing Market is poised for substantial growth. Companies in this sector must scale their offerings to meet the evolving needs of these expanding facilities, ensuring they provide innovative and reliable testing solutions that can keep pace with the industry's rapid advancements.

Report Coverage

The report “Biopharmaceuticals Manufacturing Consumables Testing Market– Forecast (2025-2030)”, by IndustryARC, covers an in-depth analysis of the following segments of Biopharmaceuticals Manufacturing Consumables Testing.

By  Service: Compendial & Multi-Compendial, Laboratory, Custom Testing / Customer Proprietary Testing 

By Geography:  North America, South America, Europe, APAC, Middle East & Africa

Key Takeaways

• In the evolving landscape of medicine, where cutting-edge science is revolutionizing patient care and treatment approaches, biopharmaceutical companies are significantly increasing their research and development (R&D) investments. Over the past decade, member companies of PhRMA have more than doubled their yearly R&D expenditures, investing nearly $101 billion in 2022 to drive advancements and breakthroughs in developing new treatments and cures. As biopharmaceutical companies invest more in R&D, there will be a corresponding need for high-quality consumables and robust testing services to ensure the efficacy and safety of new products. This led to growth opportunities in the consumables testing market.
• In the evolving landscape of medicine, where cutting-edge science is revolutionizing patient care and treatment approaches, biopharmaceutical companies are significantly increasing their research and development (R&D) investments. Over the past decade, member companies of PhRMA have more than doubled their yearly R&D expenditures, investing nearly $101 billion in 2022 to drive advancements and breakthroughs in developing new treatments and cures. As biopharmaceutical companies invest more in R&D, there will be a corresponding need for high-quality consumables and robust testing services to ensure the efficacy and safety of new products. This led to growth opportunities in the consumables testing market.
• The growing prevalence of these chronic conditions highlights an urgent need for effective and safe biopharmaceutical interventions. This demand directly impacts the biopharmaceutical manufacturing sector, particularly in the realm of consumables testing.

By Service  - Segment Analysis

Compendial & Multi-Compendial led the market with a 54.7% market share in 2024. The sustained dominance suggests that compliance with regulatory standards remains a critical priority for biopharmaceutical manufacturers, driving consistent demand for these testing services. On January 20, 2022, the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response, is organizing a Biopharmaceutical Manufacturing Consortium (BioMaC) Industry Day. This consortium represents an intended expansion of the existing National Biopharmaceutical Manufacturing Partnership (BioMaP), which is managed by BARDA's Pharmaceuticals Countermeasure Infrastructure (PCI) division. The consortium aims to enhance the collaboration between the U.S. government and the industry in the manufacturing of medical countermeasures (MCM). It will bring together industry stakeholders from across the drug and vaccine manufacturing supply chain, including producers of essential raw materials, and consumables, and providers of fill-finish services. The BioMaC initiative is likely to drive significant growth and development in the Biopharmaceuticals Manufacturing Consumables Testing Market by emphasizing the importance of quality and safety in the manufacturing of critical medical countermeasures.

By Geography - Segment Analysis

The North American region in the Biopharmaceuticals Manufacturing Consumables Testing market is anticipated to hold a major share with a CAGR of 30.3% during the forecast period (2025-2030).  The shift towards single-use systems in biopharmaceutical manufacturing is a primary driver in the North American biopharmaceutical manufacturing consumables testing market. This has led to an increased demand for testing services to validate the performance and safety of these materials under various bioprocessing conditions in the United States. Companies like Danaher and Thermo Fisher Scientific have invested heavily to meet the rising demand for single-use systems and other bioprocess consumables.

For example, Thermo Fisher invested $1 billion from 2020 to 2022 to expand its bioproduction capacity, focusing on cell culture, single-use technologies, and purification to alleviate substantial capacity limitations. Danaher has dramatically boosted its consumables spending, notably in the biopharma industry. In 2021, their capital investment in property, plant, and equipment nearly quadrupled in the first nine months, from $475 million to $874 million. Moreover, in August 2023, Danaher acquired Abcam, a prominent global provider of protein consumables to increase its position in the biopharmaceuticals market and improve its skills in mapping complicated illnesses and expediting drug discovery. This purchase emphasizes the importance of consumables in the biopharmaceutical industry and the necessity for rigorous testing to guarantee that these goods support advanced research and manufacturing. 

Drivers – Biopharmaceuticals Manufacturing Consumables Testing Market

• Increasing Use Of Single-Use Consumables Boosts The Market: 

Nowadays, preclinical to commercial manufacturing stages of the drug development cycle are seeing an increase in the utilization of single-use (SU) technologies. For instance, maintaining sterility during powder and liquid transfers or open handling through manual filling is made simpler by using single-use bioprocess containers. As the biopharmaceutical business grows and dependence on single-use production grows, the demand for SU consumables such as bags, containers, filters, and tubing is also increasing.

Companies in the single-use consumables market are also making progress by introducing cutting-edge solutions such as single-use bioreactor systems to boost their profit. For example, Getinge, a Swedish medical technology business, introduced the AppliFlex ST GMP in September 2023. This single-use bioreactor is intended for clinical cell and gene treatments, providing scalability and a smooth transition from laboratory research to clinical manufacture of mRNA synthesis, gene therapy, and cell therapy. For bioprocessing applications, these bioreactor systems use disposable components such plastic bags or containers rather from typical stainless steel or glass culture vessels.

Manufacturers must implement proper controls to manage risks associated with single-use technologies. GMP Annex 1 has a substantial influence on the utilization of single-use assemblies in fluid management operations within the biopharmaceutical sector. It requires manufacturers and stakeholders to take a risk-based approach, implement appropriate controls, and assure the integrity and sterility of single-use systems. This regulatory emphasis is boosting the demand for testing services to certify the quality and performance of single-use consumables, driving growth in the consumables testing market.

• Growing Emphasis On Quality And Safety:

The testing and analysis of raw materials, intermediates, and consumables throughout production is becoming increasingly important in ensuring the safety and quality of the finished product. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established rules to augment their good manufacturing practices (GMPs) and protect the medication supply chain. Constant improvement in regulatory requirements for biologic manufacturing includes the selection of appropriate consumables and their testing assessment. Regulations and guideline standards for region-specific pharmacopeia have also boosted raw material research to satisfy the needs of biopharma producers. The constant development of regulatory criteria for biologics manufacturing directly affects the need for consumables testing. As regulations tighten, biopharmaceutical businesses must pay more for testing and quality control methods to ensure compliance. This drives the market for biopharma manufacturing consumables testing services that can give precise and dependable findings, hence supporting the entire integrity of the biopharmaceutical production process.

Challenges – Biopharmaceuticals Manufacturing Consumables Testing Market

Complexity And Cost Poses Challenge For The Market: 

The complexity and cost of testing pose significant challenges for the Biopharmaceuticals Manufacturing Consumables Testing Market. As the biopharmaceutical industry continues to advance with more specialized and personalized therapies, the demand for consumables like filters, bags, and tubing has grown, leading to increasingly complex testing requirements. These consumables must meet stringent regulatory standards, including those set by the FDA and EMA, to ensure product safety and efficacy. However, the need for specialized testing methods, advanced technologies, and highly skilled personnel drives up operational costs, making it a barrier, especially for smaller manufacturers with limited resources. Additionally, the testing procedures for consumables often require extended timelines due to the complexity of the biopharmaceutical production process, further increasing costs. The high expense of compliance, coupled with the ongoing need to adapt to evolving industry standards, makes it difficult for manufacturers to balance quality assurance with cost-effectiveness, ultimately challenging the growth and scalability of the consumables testing market.

Market Landscape

In 2023, the top players in the Biopharmaceuticals Manufacturing Consumables Testing market share accounted for 62.1% of the share. Major players in the Biopharmaceuticals Manufacturing Consumables Testing market are Eurofins Scientific, Lonza, SGS SA, Agilent Technologies, STERIS, Catalent, Inc., Charles River, Pace Analytical Services, Alcami Corporation and Others.

Developments:

• On January 17, 2024, Alcami Corporation, a prominent contract development and manufacturing organization (CDMO), has announced the successful acquisition of Pacific Pharmaceutical Services, Inc. (PPS), a well-regarded provider of cGMP pharmaceutical storage and services. Clients of PPS will now have immediate access to Alcami’s extensive range of services, including analytical development, testing, and comprehensive drug product development and manufacturing, covering both sterile fill-finish and oral solid dose formats.
• On July 18, 2024, SGS, the global leader in testing, inspection, and certification, has announced definitive agreements to acquire two additional companies as part of its renewed M&A strategy: Analisis Quimico y Microbiologico SAS (“AQM”) and Cromanal SAS (“Cromanal”) in Colombia. Both AQM and Cromanal are significant players in the Colombian pharmaceutical testing industry.
• Eurofins finalized the acquisition of Wessling Hungary, a prominent laboratory in Budapest specializing in environmental, food, and biopharma product testing on July 2022.

For more Lifesciences and Healthcare Market reports, please click here